Back to Results

Johnson & Johnson (JNJ)

Johnson & Johnson is a healthcare company whose common stock is listed on the New York Stock Exchange under the symbol JNJ. Through its subsidiaries, the company is involved in researching, developing, manufacturing, and selling a broad range of healthcare products worldwide. Its operations are organized into two segments: Innovative Medicine and MedTech. The Innovative Medicine segment includes products used in areas such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. The MedTech segment covers products and technologies used in surgery, orthopedics, cardiovascular care, and vision, including offerings for joint reconstruction, trauma, spine, sports injuries, minimally invasive procedures, breast aesthetics, contact lenses under the ACUVUE brand, and intraocular lenses under the TECNIS brand. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-JNJ
$262.93
4.7% Upside
Fair
$269.95
7.5% Upside
Fair
Good
August 25, 2026
September 8, 2026
5.36
2.2%
October 20, 2026
28.7x
7.4x
6.2x
599 B
635.7 B
8.4%
99.8%
—
—
84.5%
Send a message
Valuation • Fair Value

Johnson & Johnson (NYSE-JNJ) Fair Value by Valuation Model

Compare the primary fair value estimate for Johnson & Johnson (NYSE-JNJ) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$262.93

Estimated upside of 4.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$96.97

Classic Ben Graham valuation formula reference.

DDM Fair Value

$320.12

Dividend discount model valuation reference.

EPV Fair Value

$148.56

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

$269.95

Analysts imply upside of 7.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Johnson & Johnson (NYSE-JNJ) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Johnson & Johnson (NYSE-JNJ)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

97.929 B

Current operating scale indicator.

Revenue Forecast

101.2 B

Forward revenue estimate.

EBITDA

34.84 B

Current operating profitability reference.

EBITDA Forecast

36.829 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Johnson & Johnson (NYSE-JNJ) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Johnson & Johnson (NYSE-JNJ)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

Not available

Data is currently unavailable.

FCF / Net Income

84.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Johnson & Johnson (NYSE-JNJ). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Johnson & Johnson (NYSE-JNJ)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

October 20, 2026

Days to Earnings

91

Dividend Payment Date

September 8, 2026

Ex-Dividend Date

August 25, 2026

Dividend Yield

2.2%

Income yield reference.

Upcoming Dividend

5.36

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Johnson & Johnson (NYSE-JNJ), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Johnson & Johnson (NYSE-JNJ) Stock Forecast & Technical Outlook

Review Johnson & Johnson (NYSE-JNJ) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Johnson & Johnson (NYSE-JNJ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Johnson & Johnson (NYSE-JNJ) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Johnson & Johnson (NYSE-JNJ) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Johnson & Johnson (NYSE-JNJ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Johnson & Johnson (NYSE-JNJ) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Johnson & Johnson (NYSE-JNJ)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Johnson & Johnson (NYSE-JNJ) has a Buy consensus, with 11 buy, 6 hold and 1 sell recommendations in the current data set.

Buy 11
Hold 6
Sell 1
FAQ • Fast Investor Answers

Johnson & Johnson (NYSE-JNJ) Stock FAQ

Quick answers about Johnson & Johnson (NYSE-JNJ) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$262.93
Estimated upside 4.7%
Valuation Rating
Undervalued
Estimated upside of 4.7%
Analyst Target
$269.95
Implied upside 7.5%
Financial Health
Good
Current financial-health read

The current fair value estimate for Johnson & Johnson (NYSE-JNJ) is $262.93. This implies an estimated upside of 4.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 4.7% versus the current market price.

The available analyst price target for Johnson & Johnson (NYSE-JNJ) is $269.95. The analyst target implies estimated upside of 7.5%.

The current financial health read for Johnson & Johnson (NYSE-JNJ) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Johnson & Johnson (NYSE-JNJ) is October 20, 2026.

Based on the current data, dividend yield is 2.2%, upcoming dividend amount is 5.36, ex-dividend date is August 25, 2026, payment date is September 8, 2026.

The current P/E ratio listed for Johnson & Johnson (NYSE-JNJ) is 28.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Johnson & Johnson is 599 B.

The current enterprise value listed for Johnson & Johnson is 635.7 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Johnson & Johnson is NYSE-JNJ, and the stock is listed on NYSE.

Johnson & Johnson (NYSE-JNJ) is listed on NYSE.

The current debt-to-total-capital ratio listed for Johnson & Johnson is 8.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Johnson & Johnson is 99.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NYSE View more

Eli Lilly and Company (LLY) Eli Lilly and Company (LLY)
Merck & Company Inc (MRK) Merck & Company Inc (MRK)
Novartis AG ADR (NVS) Novartis AG ADR (NVS)
Novo Nordisk A/S (NVO) Novo Nordisk A/S (NVO)
Pfizer Inc (PFE) Pfizer Inc (PFE)
Bristol-Myers Squibb Company (BMY) Bristol-Myers Squibb Company (BMY)
GSK plc DRC (GSK) GSK plc DRC (GSK)
Takeda Pharmaceutical Co Ltd ADR (TAK) Takeda Pharmaceutical Co Ltd ADR (TAK)
HALEON PLC ADR (HLN) HALEON PLC ADR (HLN)
Teva Pharma Industries Ltd ADR (TEVA) Teva Pharma Industries Ltd ADR (TEVA)
Zoetis Inc (ZTS) Zoetis Inc (ZTS)
Elanco Animal Health (ELAN) Elanco Animal Health (ELAN)
Dr. Reddy’s Laboratories Ltd ADR (RDY) Dr. Reddy’s Laboratories Ltd ADR (RDY)
Veradermics Inc (MANE) Veradermics Inc (MANE)
Organon & Co (OGN) Organon & Co (OGN)
Prestige Consumer Healthcare Inc (PBH) Prestige Consumer Healthcare Inc (PBH)
Nuvation Bio Inc (NUVB) Nuvation Bio Inc (NUVB)
Bausch Health Companies Inc (BHC) Bausch Health Companies Inc (BHC)
Perrigo Company PLC (PRGO) Perrigo Company PLC (PRGO)
Alto Neuroscience Inc (ANRO) Alto Neuroscience Inc (ANRO)
Rafael Holdings Inc Class B (RFL) Rafael Holdings Inc Class B (RFL)
Impact Biomedical Inc (IBO) Impact Biomedical Inc (IBO)
China Pharma Holdings Inc (CPHI) China Pharma Holdings Inc (CPHI)
Nasus Pharma Ltd (NSRX) Nasus Pharma Ltd (NSRX)